William Wierda

44PUBLICATIONS
236CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursLiquid biopsiesGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (44)

|Oct 02, 2026
Inhibition of ROR1 signaling with zilovertamab plus ibrutinib in chronic lymphocytic leukemia: safety, mechanistic insights, and an exploratory signal in del(17p) disease.

|Jul 28, 2026
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

|Apr 22, 2026
Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure.

|Mar 31, 2026
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.

Richard R Furman, William G Wierda, Piers Em Patten

|Feb 27, 2026
The Care and Cure of the Leukemias in 2026.

Hagop Kantarjian, Helen T Chifotides, Fadi G Haddad

|Feb 12, 2026
Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study.

Mahesh Swaminathan, Alessandra Ferrajoli, Philip A Thompson

Pageof 8

Frequent Collaborators

13 joint publications

Jan Burger

10 joint publications

Nitin Jain

8 joint publications

Varsha Gandhi

8 joint publications

Paolo Ghia